Top

Published in:

Open Access 01-06-2019 | Multiple Sclerosis | Commentary

An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion

Authors: Raed Alroughani, Jihad Said Inshasi, Dirk Deleu, Jasem Al-Hashel, Mustafa Shakra, Osama Robin Elalamy, Ahmed Osman Shatila, Abdullah Al-Asmi, Isa Al Sharoqi, Beatriz Garcia Canibano, Amir Boshra

Published in: Neurology and Therapy | Issue 1/2019

Abstract

This article discusses the opinions of the multiple sclerosis (MS) experts in the Gulf region on the use of high-efficacy disease-modifying drugs (DMDs; natalizumab, fingolimod, alemtuzumab, cladribine tablets, and ocrelizumab) in clinical practice. The experts reviewed the current literature including pivotal clinical trials and meta-analyses for high-efficacy DMDs, supplemented by the expert opinions on the usage of these DMDs in clinical practice. Several criteria were discussed by the panel based on different efficacy, safety, and convenience attributes. The panel concluded that all the DMDs available for the treatment of MS have benefits and risks, which should be considered while discussing the treatment plan with the patient. It is important to have a personalized approach based on the risk-benefit assessment for each case. Common considerations while choosing treatments include effectiveness, side effects/safety, and convenience/route of administration.

Funding: Merck Serono Middle East FZ LTD.

Cladribine described across the article refers to the oral formulation, Cladribine tablets.

Bar-Or A. The immunology of multiple sclerosis. Semin Neurol. 2008;28:29–45. https://doi.org/10.1055/s-2007-1019124.CrossRefPubMed

Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, Merschhemke M. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2018;90:e1815–21. https://doi.org/10.1212/WNL.0000000000005529.CrossRefPubMedPubMedCentral

Bezabeh S, Flowers CM, Kortepeter C, Avigan M. Review article: clinically significant liver injury in patients treated with natalizumab (TYSABRI™). Aliment Pharmacol Ther. 2010. https://doi.org/10.1111/j.1365-2036.2010.04262.x.CrossRefPubMed

Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009;158:1173–82. https://doi.org/10.1111/j.1476-5381.2009.00451.x.CrossRefPubMedPubMedCentral

Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9:883–97. https://doi.org/10.1038/nrd3248.CrossRefPubMed

Cheng Z, Zhang J, Liu H, Li Y, Zhao Y, Yang E. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer’s disease-related animal models despite reported blood-brain barrier disruption. Drug Metab Dispos. 2010;38:1355–61. https://doi.org/10.1124/dmd.110.033324.CrossRefPubMed

Clanet MC, Wolinsky JS, Ashton RJ, Hartung H-P, Reingold SC. Risk evaluation and monitoring in multiple sclerosis therapeutics. Mult Scler Houndmills Basingstoke Engl. 2014;20:1306–11. https://doi.org/10.1177/1352458513513207.CrossRef

Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–15. https://doi.org/10.1056/NEJMoa0907839.CrossRefPubMed

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DAS, CARE-MS I Investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet Lond Engl. 2012;380:1819–28. https://doi.org/10.1016/S0140-6736(12)61769-3.CrossRef

10.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DAS. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–39. https://doi.org/10.1016/S0140-6736(12)61768-1.CrossRefPubMed

11.

Comi G, Cook S, Rammohan K, Soelberg Sorensen P, Vermersch P, Adeniji AK, Dangond F, Giovannoni G. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY extension study. Ther Adv Neurol Disord. 2018. https://doi.org/10.1177/1756285617753365.CrossRefPubMedPubMedCentral

12.

FDA Safety Announcement. Drug safety and availability—FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug lemtrada (alemtuzumab) [WWW Document]. 2018. https://www.fda.gov/Drugs/DrugSafety/ucm624247.htm. Accessed 10 Jan 2019.

13.

Fonseca J. Fingolimod real world experience: efficacy and safety in clinical Practice. Neurosci J. 2015. https://doi.org/10.1155/2015/389360.CrossRefPubMedPubMedCentral

14.

Freedman MS. Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy. Eur J Neurol. 2014;21:377-e20. https://doi.org/10.1111/ene.12299.CrossRef

15.

Gilenya SPC. Novartis pharmaceuticals UK Ltd, Surrey, UK. European Medicines Agency. [WWW Document]. 2018. https://www.medicines.org.uk/emc/product/4545. Accessed 12 Feb 2018.

16.

Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–26. https://doi.org/10.1056/NEJMoa0902533.CrossRefPubMed

17.

Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler Houndmills Basingstoke Engl. 2017. https://doi.org/10.1177/1352458517727603.CrossRef

18.

Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan KW, Rieckmann P, Comi G, Dangond F, Hicking C, Vermersch P. Efficacy of cladribine tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: a post hoc analysis of the CLARITY study. Mult Scler Houndmills Basingstoke Engl. 2018. https://doi.org/10.1177/1352458518771875.CrossRef

19.

González-Suarez I, Rodríguez de Antonio L, Orviz A, Moreno-García S, Valle-Arcos MD, Matias-Guiu JA, Valencia C, Jorquera Moya M, Oreja-Guevara C. Catastrophic outcome of patients with a rebound after natalizumab treatment discontinuation. Brain Behav. 2017. https://doi.org/10.1002/brb3.671.CrossRefPubMedPubMedCentral

20.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–34. https://doi.org/10.1056/NEJMoa1601277.CrossRefPubMed

21.

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung H-P, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Mult Scler J Exp Transl Clin. 2018. https://doi.org/10.1177/2055217318760642.CrossRefPubMedPubMedCentral

22.

Kantor D, Johnson K, Vieira MC, Signorovitch J, Li N, Gao W, Koo V, Duchesneau E, Herrera V. Real-world persistence with fingolimod for the treatment of multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci. 2018;388:168–74. https://doi.org/10.1016/j.jns.2018.03.018.CrossRefPubMed

23.

Kappos L, Radue E-W, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401. https://doi.org/10.1056/NEJMoa0909494.CrossRefPubMed

24.

Khimani KS, Foroozan R. Central serous chorioretinopathy associated with fingolimod treatment. J Neuroophthalmol. 2018;38:337. https://doi.org/10.1097/WNO.0000000000000592.CrossRefPubMed

25.

Leist TP, Reder AT, Bermel R, Weinstock-Guttman B, Freedman MS, Cutter G, Stankiewicz J, Zheng H, Musch B, Csoboth C, Wolinsky JS. Year one interim analysis results of the phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had suboptimal response with prior disease-modifying treatments [WWW Document]. 2018. http://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/228479/thomas.p.leist.year.one.interim.analysis.results.of.the.phase.iiib.chords.html. Accessed 12 Jan 2019.

26.

Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34:28–35. https://doi.org/10.1097/WNF.0b013e318204cd90.CrossRefPubMed

27.

Lemtrada PI. Genzyme Corporation, MA, USA. Food and Drug Administration; 2018.

28.

Lemtrada SPC. Genzyme therapeutics, Oxfordshire, UK. European Medicines Agency. [WWW Document]. 2018. https://www.medicines.org.uk/emc/product/5409. Accessed 12 Feb 2018.

29.

Markowitz CE. Multiple sclerosis update. Am J Manag Care. 2013;19:s294–300.PubMed

30.

Mavenclad SPC. Merck Serono Europe Limited, London, UK. European Medicines Agency. [WWW Document]. 2018. https://www.medicines.org.uk/emc/product/8435/smpc. Accessed 12 Feb 2018.

31.

Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RLP, Kappos L. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008;71:1261–7. https://doi.org/10.1212/01.wnl.0000327609.57688.ea.CrossRefPubMed

32.

Menon S, Shirani A, Zhao Y, Oger J, Traboulsee A, Freedman MS, Tremlett H. Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84:1192–8. https://doi.org/10.1136/jnnp-2013-304951.CrossRefPubMed

33.

Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, Fisher E, O’Connor PW, Phillips JT, Polman CH, Kappos L, Hutchinson M, Havrdova E, Lublin FD, Giovannoni G, Wajgt A, Rudick R, Lynn F, Panzara MA, Sandrock AW, Investigators AFFIRM. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007;68:1390–401. https://doi.org/10.1212/01.wnl.0000260064.77700.fd.CrossRefPubMed

34.

Moss B, Utigard E, Baldassari L, Cohen J, Ontaneda D. Real-world experience with ocrelizumab (P6.356). Neurology. 2018;90:P6.356.

35.

NICE Pathways. Disease-modifying therapies for multiple sclerosis. 2018.

36.

Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343:938–52. https://doi.org/10.1056/NEJM200009283431307.CrossRefPubMed

37.

Ocrevus SPC. Roche Products Limited, Hertfordshire, UK. European Medicines Agency. [WWW Document]. 2018. https://www.medicines.org.uk/emc/product/8898. Accessed 12 Feb 2018.

38.

Pinschewer DD, Brinkmann V, Merkler D. Impact of sphingosine 1-phosphate modulation on immune outcomes. Neurology. 2011;76:S15–9. https://doi.org/10.1212/WNL.0b013e31820d9596.CrossRefPubMed

39.

Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910. https://doi.org/10.1056/NEJMoa044397.CrossRefPubMed

40.

Rau D, Lang M, Harth A, Naumann M, Weber F, Tumani H, Bayas A. Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis-report of two cases. Int J Mol Sci. 2015;16:14669–76. https://doi.org/10.3390/ijms160714669.CrossRefPubMedPubMedCentral

41.

Rice GPA, Hartung H-P, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology. 2005;64:1336–42. https://doi.org/10.1212/01.WNL.0000158329.30470.D0.CrossRefPubMed

42.

Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol. 2015;11:379–89. https://doi.org/10.1038/nrneurol.2015.85.CrossRefPubMed

43.

Schaeffer J, Cossetti C, Mallucci G, Pluchino S. Chapter 30—Multiple sclerosis. In: Zigmond MJ, Rowland LP, Coyle JT, editors. Neurobiology of brain disorders. San Diego: Academic Press; 2015. p. 497–520. https://doi.org/10.1016/B978-0-12-398270-4.00030-6.CrossRef

44.

Sempere AP, Berenguer-Ruiz L, Feliu-Rey E. Rebound of disease activity during pregnancy after withdrawal of fingolimod. Eur J Neurol. 2013;20:e109–10. https://doi.org/10.1111/ene.12195.CrossRefPubMed

45.

Sharrack B, Mayer L, Coles A, Hartung H-P, Havrdova E, Selmaj K, Margolin D, Compston A. Management of adverse reactions to alemtuzumab infusion. J Neurol Neurosurg Psychiatry. 2015;86:e4. https://doi.org/10.1136/jnnp-2015-312379.119.CrossRef

46.

Singer BA. The role of natalizumab in the treatment of multiple sclerosis: benefits and risks. Ther Adv Neurol Disord. 2017;10:327–36. https://doi.org/10.1177/1756285617716002.CrossRefPubMedPubMedCentral

47.

Thompson SAJ, Jones JL, Cox AL, Compston DAS, Coles AJ. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol. 2010;30:99–105. https://doi.org/10.1007/s10875-009-9327-3.CrossRefPubMed

48.

Trial ID: NCT01013350. Prospective observational long-term safety registry of multiple sclerosis patients who have participated in cladribine clinical trials—full text view—ClinicalTrials.gov [WWW Document]. 2018. https://clinicaltrials.gov/ct2/show/NCT01013350. Accessed 14 Dec 2018.

49.

Tysabri SPC. Biogen Idec Ltd, Berkshire, UK. European Medicines Agency. [WWW Document]. 2018. https://www.medicines.org.uk/emc/product/222. Accessed 12 Feb 2018.

50.

Vargas WS, Perumal JS. Fingolimod and cardiac risk: latest findings and clinical implications. Ther Adv Drug Saf. 2013;4:119–24. https://doi.org/10.1177/2042098613481023.CrossRefPubMedPubMedCentral

51.

Winkelmann A, Loebermann M, Reisinger EC, Hartung H-P, Zettl UK. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol. 2016;12:217–33. https://doi.org/10.1038/nrneurol.2016.21.CrossRefPubMed

Title: An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion
Authors: Raed Alroughani
Jihad Said Inshasi
Dirk Deleu
Jasem Al-Hashel
Mustafa Shakra
Osama Robin Elalamy
Ahmed Osman Shatila
Abdullah Al-Asmi
Isa Al Sharoqi
Beatriz Garcia Canibano
Amir Boshra
Publication date: 01-06-2019
Publisher: Springer Healthcare
Keywords: Multiple Sclerosis
Ocrelizumab
Expert Opinion
Expert Opinion
Natalizumab
Fingolimod
Alemtuzumab
Cladribine
Ocrelizumab
Alemtuzumab
Published in: Neurology and Therapy / Issue 1/2019
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI: https://doi.org/10.1007/s40120-019-0129-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Neurology and Therapy: Looking Back on 2018 and Forward to 2019

Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes

Treatment Patterns, Healthcare Resource Utilization, and Costs Among Medicare Patients with Multiple Sclerosis in Relation to Disease-Modifying Therapy and Corticosteroid Treatment

Risperdal® CONSTA® Needle Detachment. Incidence Rates Before and After Kit Redesign: A Retrospective Study using Electronic Health Records and Natural Language Processing in the Department of Veterans Affairs

Emerging Immunotherapies for Parkinson Disease

Cerebrolysin as a New Treatment Option for Post-Stroke Spasticity: Patient and Physician Perspectives